Baird Medical's 2025 Revenue Drops 39% Amid China Headwinds; Appoints U.S. CEO to Drive Expansion

What happened

Baird Medical reported full-year 2025 revenue of $22.5 million, down sharply from $37.0 million in 2024, citing a policy-driven slowdown in Mainland China that impacted sales of its microwave ablation devices. The company appointed Mark Saxton as CEO of Baird Medical U.S. to lead commercial ramp in the United States, a strategic move to diversify beyond its heavily China-dependent revenue base. Despite this, the company's financial quality remains poor: it has generated negative free cash flow for three consecutive years, driven by rising trade receivables and prepayments that have not converted to cash. The stock trades at a P/E of roughly 2.4x and P/B of 0.8x, reflecting structural risks including material internal control weaknesses, customer concentration, and concentrated PRC regulatory exposure. The revenue decline confirms that near-term growth is under severe pressure, and the U.S. effort, while promising, is unlikely to offset China headwinds in the near term.

Implication

If Baird executes its U.S. strategy and remediates internal controls, the current low multiples could present a multi-year value opportunity; however, the risk of continued cash burn, further revenue erosion, and dilution from warrants and preferreds remains high, warranting a cautious stance.

Thesis delta

The prior thesis highlighted low multiples and niche leadership but flagged cash flow and governance risks; the sharp 2025 revenue decline and continued negative free cash flow shift the risk/reward further toward caution. The U.S. CEO appointment offers a potential diversification pathway, but execution risk is elevated and earnings quality remains poor, making the stock more speculative than before.